Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTIVION, INC.CRY · Entity 4767 | VP, Clinical Research | March 12, 2021 | March 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTIVION, INC.
Report date March 12, 2021 · Filed March 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,203 |
Ending reported balance
After 2021-03-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-03-12 · Tax withholding · Disposed 1,160 · Balance 153,436 F1: Represent shares of restricted stock that were withheld for taxes on the grant vest date. Row 2 · 2021-03-12 · Tax withholding · Disposed 233 · Balance 153,203 F2: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent shares of restricted stock that were withheld for taxes on the grant vest date.
F2: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2017 Filed Feb 22, 2017 23:33 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 785 | $17.25 | $13,541.25 |
DisclosureSEC source: 0000784199-17-000009 · certent-form4.xml · nonDerivative · entry 3 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,642 F1 · shares: These shares were withheld upon the vesting of restricted stock to pay tax withholding obligations. Read SEC document |
| February 19, 2017 Filed Feb 22, 2017 23:33 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 10,471 | $17.25 | $180,624.75 |
DisclosureSEC source: 0000784199-17-000009 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,113 F2 · shares: Represents performance stock units granted on February 19, 2016 and earned at approximately 142.2% of target based on 2016 adjusted EBITDA. Fifty percent (50%) were issued on February 19, 2017. The remaining shares earned in connection with the February 2016 grant will vest and be issued as follows: 50% on 02/19/2018, and 50% on 02/19/2019, assuming continued employment on the relevant vesting date. Read SEC document |
| February 19, 2017 Filed Feb 22, 2017 23:33 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 1,747 | $17.25 | $30,135.75 |
DisclosureSEC source: 0000784199-17-000009 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,366 F1 · shares: These shares were withheld upon the vesting of restricted stock to pay tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.